Neoadjuvant chemotherapy in bladder cancer: not a matter on how much but on who it is effective

Giovanni Motterle, R. Jeffrey Karnes


In this study published in Urologic Oncology, Waingankar and the group form Mount Sinai (1) perform an analysis on the impact of pathological complete response to neoadjuvant chemotherapy (NAC) in muscle-invasive bladder cancer (MIBC) on conditional surviving, meaning the updated probability of surviving after having survived each additional year after the treatment.